• The increased driving range and expansion of charging outlets are expected to trigger widespread adoption of EVs, including commercial EVs
• The commercial EV segment is projected to grow at a 41.1% CAGR from 2020-2028 and is likely to influence the purchase of other types of EVs, further benefiting Ideanomics’ Mobility division
• Ideanomics Capital division, through wholly owned subsidiary Timios, is set to benefit from the pandemic-driven growth currently being witnessed in the housing market

The global electric commercial vehicle market is expected to grow at a CAGR of 41.1% from 2020 to 2028, reaching a little over 2 million units in sales on the back of advancements in battery technology, electrification of public transportation fleets and stricter government regulations on pollution, per a Research and Markets forecast (https://ibn.fm/AZ0TM).

Similarly, a 2020 Deloitte article (https://ibn.fm/UAh8f) noted that the removal of two of the biggest barriers for consumers, namely driving range and the lack of charging infrastructure over the next few years, portends good tidings for the electric vehicle (“EV”) industry. The article further observed that the proliferation of commercial EVs (lorries, trucks and vans) and mass transit vehicles (buses) would instill even more confidence in consumers as to the reliability of EVs, influencing them to purchase the other types of EVs.

Based on these predictions, Ideanomics (NASDAQ: IDEX) is positioned favorably, given its Ideanomics Mobility division is focused on the EV market. This division comprises over five companies, including Medici Motor Works, which operates in the electric commercial vehicle segment, offering zero-emission trucks, vans and buses. Others are Mobile Energy Global (“MEG”), Wireless Advanced Vehicle Electrification (“WAVE”), Treeletrik, Energica, Solectrac and Silk EV.

“2020 was the year for passenger EV… But 2021 is the year that the commercial (‘EVs’) start to become mainstream; this is when companies like Ideanomics and others are going to shine,” stated Ideanomics CEO Alf Poor in a presentation at the 23rd Annual Needham Growth Conference (https://ibn.fm/H74nP) earlier this year. Alf went on to quote Bloomberg New Energy Finance (“BNEF”), which estimates that global commercial EV sales will reach 1.2 million units in 2023.

Ideanomics, which wholly owns Medici Motor Works, is set to capitalize on this expected growth in demand, which is projected to remain consistent through 2040, per BNEF’s long-term electric vehicle outlook. By 2040, EVs will account for 67% of all public buses and 24% of all light commercial vehicles. At the same time, Ideanomics’ Treeletrik and Energica subsidiaries, manufacturers of two-wheelers, will also benefit as 47% of all motorbikes sold in 2040 will be electric (https://ibn.fm/VXfmf).

The future also holds great promise for IDEX’s second division, Ideanomics Capital, which focuses on providing disruptive fintech solutions covering a broad range of financial services. The division is made up of five companies: Timios, DBOT, Liquefy, Intelligenta and Technology Metals Market (“TM2”). In his presentation, Alf singled out Timios, praising its data-driven approach to closing more property refinancing and purchasing within the broader real estate sector.

But, why Timios? What has made real estate stand out? The housing market is currently “in a frenzy like no other since the 2008 crisis”, occasioned by higher demand for housing than there is supply (https://ibn.fm/eXDbm). The pandemic is credited for this phenomenon because some companies relocated at the height of the outbreak, causing surges in demand for housing in certain cities. Further, the work-from-home policy encouraged employees to upgrade their homes, either through renovations or by purchasing new homes, with the latter contributing to the surge in demand (https://ibn.fm/Q6can).

Remarkably, in his presentation, Alf had foreseen this imminent vibrancy of the housing market, which, as he had observed, would greatly favor Timios. “Companies like Timios can make a lot of money. These guys made $3 million EBITDA in December alone. So, we’re going to expect big things from them,” Alf added. Over the coming period, Ideanomics plans to inject more capital into Timios to help it grow more efficiently.

For more information, visit the company’s website at www.Ideanomics.com.

NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Approximately 50% of patients who have bladder cancer will see a recurrence of the condition – often due to poor margin visibility
• White light has been the standard procedure during cystoscopies, but is only beneficial if tumors protrude from the bladder wall
• Blue light cystoscopies address this issue, increasing the odds of removing more cancerous cells and reducing the recurrence of the cancer
• The i/Blue Imaging System(TM) improves surgical technique by combining both white and blue light capabilities on one screen without the necessity of switching between two images
• Imagin Medical Inc. is currently moving toward commercializing the system, expecting to complete the product in 2022

Approximately 50% of patients who suffer from non-muscle-invasive bladder cancer will relapse. Even with the rates of local recurrence after definitive therapy improving, research indicates that management of the disease remains a challenge. Urothelial carcinoma, the most common type of bladder cancer, continues to exhibit high rates of recurrence (https://ibn.fm/4HXcP).

The primary treatment for recurrence focuses on cytology, stage, and clinical characteristics. A particular area of interest is identification and causes/predictors of urothelial carcinoma recurrence. Differentiating management of recurrent carcinoma from treatment of primary carcinoma has generated limited progress, but the research indicates that organ-conserving and endoscopic therapies may be effective, especially by identifying patients who are facing a higher risk of early recurrence.

This is where technologies such as Imagin Medical’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) may prove effective by enhancing tumor visualization and resection, and potentially lowering recurrence rates as a result.

Focused on establishing a new standard of care in the visualization of cancer during minimally invasive procedures, Imagin Medical’s primary focus is bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common on men. Due to its high recurrence rate, patients who have had bladder cancer require years of follow-up testing and procedures to catch recurrence early, making it one of the most expensive cancers to treat (https://ibn.fm/tus7H).

The conventional method used to visualize bladder cancer during surgical procedures is called a cystoscopy. Cystoscopies allow medical providers to see inside the bladder using a thin, lighted, flexible tube called a cystoscope, which uses white light to illuminate the area. White light has been the standard of care for decades and is used by more than 90% of the cystoscopy procedures. While white light effectively shows the landscape of the bladder, it is not effective in visualizing all cancerous tissue that may be present in the bladder, only tumors that protrude above the surface.

Since 2010, the use of blue light paired with a reactive contrast agent during cystoscopies has been expanding as a promising new visualization method that highlights cancerous cells, including margins and flat tumors along the bladder wall. The problem with using blue light during cystoscopies is that the images are not in real time, requiring surgeons to switch back and forth, during the intervention, between the real-time white light image and the blue light image that highlights the cancer.

Imagin’s i/Blue Imaging System aims to address these shortcomings. Combining the effectiveness of blue light cystoscopy with proprietary technology, the i/Blue Imaging System will improve surgical technique by displaying both white and blue light images simultaneously side-by-side in real time on one monitor. This innovation will enable the surgeon to view cancerous cells and their margins in context for more complete removal eliminate the need to switch back and forth to resect the cancer.

Imagin is currently moving toward commercialization of its technology, with the Food and Drug Administration approval process underway. The company is working with Maine-based Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified manufacturer, to finalize the system design for manufacture. The product is on track for completion in 2022 (https://ibn.fm/TKiU1).

Once the goal of changing bladder cancer visualization has been realized, Imagin will build on the i/Blue Imaging System’s technology to facilitate other minimally invasive procedures, including laparoscopic, colorectal, and thoracic that use a variety of contrast dye agents and illumination sources. Imagin is working to improve upon past technology, create better patient outcomes, and incur fewer costs in the process.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Mobius.Bet will be showcased in all 8 stadiums during the Brazil FIFA World Cup Soccer qualifiers – the opening salvo of its launch into the lucrative Brazilian market
• There will be an estimated 35 to 40 million viewers per match
• With over 76 million gamers, Brazil is the largest and fastest-growing Esports and gaming market in Latin America

Mobius Interactive, an online Esports and gaming operator, is expanding into the Brazilian market. The Company announced in a recent press release (https://ibn.fm/Pj2uL) that the Mobius.Bet brand will be displayed prominently in every stadium and on Globo TV for all eight World Cup qualifiers in Latin America. Soccer is the biggest sport in the world and Brazil is a soccer powerhouse. Brazil holds more World Cup victories than any other team; they have qualified for every World Cup they have entered. The 2021 qualifiers begin June 3 and run through November 16. These critical matches will attract an average audience of 35 million people on Globo TV. The match against Argentina, Brazil’s biggest rival, is expected to top 40 million viewers. In the words of Mobius Interactive CEO Lynn Pearce: “As we go to market in Brazil with this great opportunity, Mobius.Bet will be showcased on Globo TV and in every stadium, featuring the best teams in Latin America. I don’t believe we could have wished for a better launch pad to introduce ourselves to the sports enthusiasts and betting community in this region. The team at Mobius are ecstatic to be a part of these events; we are just as excited about the games as the fans are – all the way to Qatar in 2022.” These stadiums have enormous capacities (between 38,755 and 78,838). While these crowd potentials are very impressive, remember you are buying into the massive Brazilian TV audience. Globo TV Network reaches 99.5% of potential viewers, practically the entire Brazilian population of over 211 million. With over 76 million gamers, Brazil is the biggest Esports and iGaming market in Latin America. This industry is currently experiencing unprecedented growth. Mobius is strategically positioned, poised to take full advantage of this lucrative, emerging market. The Mobius team launched in September 2020, after years of working and consulting within the iGaming industry. With over 40 years of hands-on industry experience and having launched over 30 successful products globally, Team Mobius knew exactly what modern players wanted. Mobius is now uniquely positioned to offer today’s sophisticated players the best customer service possible. Our loyalty and gamification programming is meticulously designed by top industry experts, to engage and retain Esports enthusiasts and sports betting players alike. Mobius launched three diverse brands within an incredible timeframe of only three months in 2020, setting a record in the gaming industry: Mobius.Bet, AragonCasino.com, and ClubDouble.com. Mobius.Bet is designed to appeal to Esports consumers aged 18 to 38, combining loyalty programs, targeted gamification, and product merchandising into one seamless package. Catering to consumers aged 21 to 45, AragonCasino.com brands itself along the lines of medieval and modern fantasy, mimicking elements of The Walking Dead and Game of Thrones. Club Double targets the 30 to 65 age demographic, showcasing a theme that combines classic old Hollywood and vintage Miami/Las Vegas. Mobius has set itself apart from other gaming platforms through affiliate marketing groups, a focus on Esports, real-time customer relationship management, and a unique loyalty and gamification program. Now it’s time to bring the premier Mobius gaming experience to Brazil. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• RYAH has released April 2021 Patients Patterns in New York Report to bring invaluable data-driven insights within the plant-based health industry amid recent recreational cannabis legislation change in this state.
• The company leveraged data from 4,387 New York patients within the RYAH Data ecosystem to discover New York-based patients’ profiles, including their preferences and medical reasons for use.
• As an authority in dose-control technology for plant-based medicine, RYAH appears well placed to capitalize on growing market opportunities.

RYAH Group (CSE: RYAH) (formerly known as Prime Blockchain Inc.) has announced the release of its “April 2021 Patients Patterns in New York Report,” covering data generated by 4,387 patients from New York who logged their sessions within the RYAH Data ecosystem between January 1, 2018, and April 15, 2021 (https://ibn.fm/ScF8T). As an authority within the dose-control technology for plant-based medicine, RYAH leverages access to a wealth of data helping open up new knowledge-enabled possibilities within the health industry. The newly published report is the latest such initiative — especially invaluable since the recent legislative approval of recreational cannabis in March 2021.

Home to one of the wealthiest cities in the world, New York state accounts for 8% of US GDP. It is expected to become one of the largest US plant markets, with recreational cannabis sales potentially reaching $1.2 billion by 2023 and up to $4.2 billion by 2027. With these market expectations, it is of critical importance to understand who a New York-based patient is, what their preferences are, and what medical conditions they use cannabis for.

As a data analytics health care company collecting anonymized data generated by patients, RYAH is ideally placed to answer these questions. The Company is committed to developing cutting-edge technology to generate powerful analytics by combining dosing data with lab test information and patient feedback to create a personalized self-optimizing experience.

The report gives invaluable insights into the New York medical cannabis space, comparing it to the national average. It reveals that these patients are more likely to be male (65.5%) than patients at the national level (54.8%) while they have slightly less experience with the plant and use it less frequently. For example, 7% of patients from New York use it daily, compared to the national average of 8.4%. On the other hand, and in line with national averages, New York patients prefer cultivars with higher THC content or a CBD-rich profile. More sessions from New York-based patients were logged on the RYAH platform for anxiety, social anxiety disorder, and ADHD than patients from other parts of the country. RYAH Data ecosystem also reveals that conditions such as stress and depression are more prevalent in New York patients.

After launching in a limited capacity in 2016, New York State’s medical cannabis program served more than 143,000 patients. In March 2021, the state approved the legislation covering recreational cannabis, becoming the 15th state to legalize recreational use (https://ibn.fm/rFWL5). Several amendments are introduced to improve access to medical cannabis, covering a wide range of qualifying conditions, including cancer, HIV, Parkinson’s disease, multiple sclerosis, spinal cord injury, epilepsy, inflammatory bowel disease, neuropathy, Huntington’s disease, PSTD and chronic pain. As a go-to provider of data analytics expertise for the plant-based medical industry, RYAH appears ideally placed to capitalize on the growing market opportunity as New York positions itself to become one of the nation’s largest markets of legal cannabis and the plant-based legislation continues to evolve nationwide.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the Company’s newsroom at https://ibn.fm/RYAH

• April analyst reports all point to a bright future for Cybin
• “CYBN is a true multi-molecule company that’s not being reflected in its valuation,” reports Stifel
• “With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined,” notes Roth

A series of recent analyst reports bodes well for Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics. April reports from Canaccord Genuity equity research company, Stifel GMP (https://ibn.fm/aQ9af) and Roth Capital Partners (https://ibn.fm/YkBNb) all categorize Cybin as a buy, with Stifel increasing its price target from $5 to $11, Roth noting a $10 per share price target, and Canaccord coming in at $8.

In its report increasing Cybin’s price target, Stifel noted that “CYBN is a true multi-molecule company that’s not being reflected in its valuation.” The report further observed, “CYBN has been progressing rapidly along its path of developing a pipeline of novel psychedelic molecules, transforming the company from a single molecule strategy to a more diversified one with stronger IP opportunities.”

The report noted that the company’s proprietary CYB003, a novel 2nd-generation tryptamine, has undergone proof-of-concept studies and that the company is targeting alcohol use disorder, a relapsing disease with high unmet needs, a large addressable market and low competition. “We believe CYBN’s shares have a direct pathway for over ~3.5x upside near term as neither its primary candidate nor its first novel candidate — expected to enter clinical trials in 2021 — is fully accounted for in its valuation, offering investors with an attractive entry point,” the analysis concluded.

As a basis for initiating coverage of Cybin, the Roth analysis reported the following: “Overlooked by the pharmaceutical industry, Cybin found, in our opinion, ingenious ways to improve potency and delivery of psychedelic drugs by reformulation and by exploring deuterated analogues. Along the way the company created novel intellectual property to fend off competition.

“According to a recent study by Imperial College London, psilocybin may actually be superior to an SSRI [selective serotonin reuptake inhibitor], escitalopram, in patients suffering from major depressive disorder,” the report continued. “However, each psilocybin treatment session may last 6-8 hours, when administered orally. Cybin’s sublingual formulation bypasses the stomach, as the drug enters the bloodstream through the oral mucosa for faster onset of action. . . . TRD (treatment resistant depression) impacts over 1% of the population, unfortunately. With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined, according to our calculation.”

In its report, Canaccord noted that an academic group from Imperial College London published long-awaited results from its Psilodep-RCT study in the “New England Journal of Medicine.” The study analyzed the treatment of patients with long-standing, moderate-to-severe major depressive disorder (“MDD”) over a six-week period.

“The results did not hit on the primary endpoint but were in favor of psilocybin on the primary and every secondary outcome measure,” the analysis noted. “We view the results from this relatively small trial as encouraging for the potential use of psilocybin in the depression setting. We also believe the results support the investigation of psilocybin in larger, multi-center trials, which CYBN eventually expects to pursue.”

An earlier Canaccord Genuity report noted that Cybin is using a proprietary drug discovery platform combined with novel delivery and formulation technologies to develop innovative psychedelic therapeutics to treat psychiatric disorders. After hosting several investor meetings with Cybin executives, Canaccord reported that “investor focus was on the upcoming Phase 2 program for [Cybin’s] lead product, CYB001, which is a sublingual film formulation of psilocybin to treat major depressive disorder (“MDD”). CYBN expects to start a Phase 2a trial in Jamaica (West Indies). The company then expects to file an investigational drug (“IND”) application and start a Phase 2b trial, which will include US sites, soon after.” Observing that “all eyes are on the Phase 2a data,” Canaccord called CYB001 a near-term catalyst for CYBN.

Canaccord also reported that investors are focused on the evolving intellectual property (“IP”) situation around psilocybin and that CYBN intends to uplist to a major US exchange shortly. “So we note this is a very interesting period for CYBN both as a company and as a stock, and we are reiterating our BUY rating,” the report concluded.

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug- discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Leasing agreements provide a combined 28,483 square feet of space
• Additional space allows company to work towards several long-term business objectives
• Company eyeing R&D, in-house manufacturing, and formation of company divisions created to support strategic expansion plans

With its focus on continued growth and innovation, TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP2) recently signed lease agreements for two facilities in Las Vegas; the buildings are located in the Hughes Airport Center business park, which is conveniently located near the McCarran International Airport (https://ibn.fm/CApMM). In the announcement, TAAT noted that the agreements provide a combined 28,483 square feet of space, which the company intends to use for research and development, manufacturing, warehousing, and distribution management. The facilities will also provide office space for executives’ operational staff as well as ample room for conferences and other TAAT events. “As the company begins to scale its market presence in 2021 following the recent announcement of a CAD $149,000 purchase order intended for distribution in the United Kingdom and Ireland, as well as sustained operations in Ohio and online across the United States through e-commerce, TAAT is proactively assembling an expanded corporate infrastructure to facilitate anticipated growth,” the announcement stated. “The company believes that with these facilities at its disposal, it will be better positioned to work towards several of its long-term business objectives.” Those objectives include R&D, in-house manufacturing, a contact center and customer experience management center, as well as the formation of company divisions created to support the company’s strategic expansion plans. The new facilities provide space for internal labs dedicated to evaluating future iterations of the company’s flagship product, TAAT(TM), as well as additional products that may be developed. In addition, the 250% increase in available space will allow the company to significantly grow its manufacturing process. Currently the company produces enough material for an estimated 680,000 10-pack cartons of TAAT a year; the 250% increase in available space provides room for significant production capability growth. Other plans include establishing an internal contact center for current and prospective customers to reach out to TAAT, as well as global distribution division that would monitor distribution channels, prioritize shipment dispatching, gather market and supply chain intelligence, and work directly with warehouse personnel to optimize distribution operations. TAAT also anticipates needing office space for its growing number of employees, many working in new operational divisions that could include sales, marketing, digital content production, social media, event management and legal. The lease agreements also provide conference and meeting spaces to enable internal collaboration as well as for hosting meetings with clients, vendors, and service providers. TAAT identified the Hughes Airport Center as an ideal location for the growing company because of its close proximity to the airport, which is the eighth busiest airport in the country, as well as I-15 and I-215, which provide easy access for transport of goods. TAAT Lifestyle and Wellness has developed TAAT, a tobacco-free and nicotine-free alternative to traditional cigarettes available in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, visit the company’s websites at www.TryTAAT.com and www.TAATGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

• DGTL averaging a +70% revenue growth for 2021 (vs. previous FYTD)
• DGTL is seeking to build a portfolio of high growth martech software assets via M&A, targeting Social Media, Gaming, A/V Streaming and Analytics software
• Wholly owned Hashoff LLC – an enterprise-level social media influencer content management software serving global brands such as Anheuser Busch, Dunkin Brands, Syneos Health, DoorDash, Shein, Veritone, Dentsu, Publicis Groupe, etc.
• Hashoff recently signed Beam Suntory – the third-largest producer of premium distilled product brands worldwide, with 4,800 employees, large distilleries in several countries, and owner #1 selling bourbon brand in the world, Jim Beam
• Recent campaigns at the NCAA March Madness and PGA Masters for new client signing DraftKings, a global leader in digital sports entertainment and gaming
• DGTL funding Hashoff 2.0 for Tiktok, SnapChat, Youtube – ETA June of 2021

DGTL Holdings (TSX.V: DGTL) (OTCQB: DGTHF), a venture capital asset management company focused on the acquisition and acceleration of digital media, marketing technology (martech), and advertising technology (adtech) powered by artificial intelligence (“AI”), has released financial results for both the three-month and nine-month periods ending February 28, 2021, which represents the Q3 and YTD financial results for FYE 2021 (https://ibn.fm/4gxtZ). DGTL reported that ending February 28, 2021, total revenue for the three-month period reached $1,250,782, while revenue for the nine-month period was $3,666,603. The latter figure marks a 71% growth in revenue compared to the same nine-month period of 2019, when reported revenue was $2,142,484, stemming their first acquisition, Hashoff LLC. Hashoff LLC, also known as #HASHOFF, is an enterprise-level social media influencer content management software (“CMS”) solution. The focal point of #HASHOFF is global brands and leading advertising agencies. The CMS platform enables marketers to leverage the “gig” economy by identifying, scanning, optimizing, engaging, and managing over 150 million freelancer’s content to geo-target event-marketing, brand content among all languages, regions, and product categories. Commenting on Hashoff’s growth, Steven Goldberg, DGTL’s Chief Operating Officer, stated that the subsidiary has executed well during challenging market conditions. “Hashoff’s operational team has delivered revenue growth and a global brand customer base. The DGTL leadership team is pleased with Hashoff’s initial business development achievements. We look forward to continued momentum,” Goldberg added. Hashoff serves global brands in many different industries, including the CPG, health, sports entertainment, gaming, and retail sectors. DGTL reports that the subsidiary has added major new contracts since February 28, 2021, the end of the Q3 financial reporting date. One major client that Hashoff signed a new campaign activation contract with is DraftKings (NASDAQ: DKNG), a leader in the global digital sports entertainment and gaming industries (https://ibn.fm/2Rqz0). Another of these contracts is a new software service agreement between Hashoff and the third-largest producer of premium distilled brands globally, Beam Suntory. Under the agreement, Hashoff’s initial campaign for Beam Suntory will consist of video-based influencer content that showcases innovative product applications to the consumer market globally. Hashoff successfully implemented the same type of alternative digital marketing content distribution strategy in other recent campaigns for major global brands (https://ibn.fm/zLCOv). Beam Suntory owns the top-selling bourbon brand globally. It is recognized as the first to bring premium Japanese single malt brands to a global market via a $16 billion acquisition. Additionally, the company owns large-scale distilleries in Scotland, Spain, Japan, Mexico, and the United States. It has more than 4,800 employees, with headquarters in Chicago and offices in Osaka, Japan. DGTL has a vision of building a diversified portfolio of fully commercialized enterprise level digital media and martech software companies to be a full service platform for global brands. DGTL is an AI tech accelerator that grows revenue, IP and profitability of its subsidiaries via;

• Business Strategy: DGTL provides leadership in software engineering, executive management, recruitment, PR-marketing, business development, corporate services
• Capital Markets: sourcing venture capital via debt, equity, and public offerings, including financial modeling, due diligence, investor materials, capital roadshows, etc.
• Mergers and Acquisitions: DGTL’s deal desk committee and custom proprietary valuation system identifies new opportunities to acquire, fund and accelerate digital media and marketing technology companies, to build a diversified portfolio of assets
• Growth Partnerships: DGTL collaborates on CMO-level buy-side relationships with global fortune 100 level brands, as well as building new channel partnerships with leading agencies and complimentary technology accelerators and venture capital funds, to expand its base of subsidiary companies, and their customers.

To empower innovation, DGTL partners with growth-stage enterprise software companies, adding leadership, strategic planning, and valuable resources to the company’s overall portfolio. DGTL advances development while streamlining operations in a scalable and sustainable way through senior executives and an expert advisor network who provide the tools, technology, expertise, networks, and resources to maximize growth in subsidiary companies. For more information, visit the company’s website at www.DGTLInc.com. NOTE TO INVESTORS: The latest news and updates relating to DGTHF are available in the company’s newsroom at https://ibn.fm/DGTHF

• ISW Holdings announces financial performance for 2020, with telehealth reporting 69% revenue and 276% asset growth
• Company expects best yet to come with 2021 revenues at least tripling 2020 topline performance as crypto mining business starts to yield results
• ISWH looks ahead to expansion of crypto presence, uplisting on OTCQB

Despite pandemic-related challenges, 2020 was the year of dramatic transformation for ISW Holdings (OTC: ISWH), leading to much bigger expectations in 2021. The global brand management company, which has strategically invested in telehealth and cryptocurrency mining, has issued updates on 2020 financial performance and business plans for the quarters ahead (https://ibn.fm/zzBXV). Over the past two years, the company demonstrated steady growth, driven mainly by its telehealth and home healthcare division investments. ISWH believes this success is only the beginning, and the best is yet to come as this financial data predates the launch of its cryptocurrency mining and mining equipment segment. ISWH believes the revenue growth is set to continue as returns on investments in its cryptocurrency mining and mining equipment begin to reflect in 2021. More specifically, the company expects full-year 2021 revenues to at least triple 2020 topline performance (https://ibn.fm/chK1Z). Financial highlights for the year ended Dec. 31, 2020, demonstrate year-over-year gross revenues growth of 69% for the company’s telehealth joint venture, Paradigm Home Health, where ISW Holdings earns 50% of the net profit or loss. Telehealth business line provides robust and steady cash flows for the company while its mining segment gets up to full speed. With multiple orders of new miners available immediately and a batch of new ones that will be manufactured and ready to ship in August, ISWH appears poised to increase the mining capacity and capitalize on the current market environment. It appears that ISWH will not stop there as the company is building its presence in a mining project in Georgia with at least a $500–700k per month opportunity from this expansion. The current cryptocurrency market is on the upswing as investor interest in digital currencies was surging over the recent months. Crypto mining is an essential part of a cryptocurrency ecosystem as miners keep the blockchain secured and trustworthy as they validate new transactions and record them on the global ledger blockchain through millions of computers worldwide. The global mining hardware market is expected to increase by $2.8 billion during 2020–2024, growing at a CAGR of 7% during the period (https://ibn.fm/JppJJ). At the end of last year, ISWH committed to an anti-dilution initiative announcing negotiations with noteholders to protect the value of its common stock. As of this month, the company has eliminated more than $3.4 million (94%) of outstanding convertible debt, believing that this move not only removes shareholders dilution risk but also boosts its ability to attract top talent and execute on new partnership and acquisition opportunities (https://ibn.fm/Ai28P). ISW Holdings appears to have big plans for 2021. With several minor steps remaining in the process of uplisting on the OTCQB, plans are on track for its public market debut. “We are at the bottom of the hockey stick as far as growth potential, with a clean bill of health on the balance sheet and major new non-dilutive funding providing us with a strong capital foundation to continue aggressive expansion in cryptocurrency mining and mining equipment,” said ISW Holdings president and chairman Alonzo Pierce. For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• StorEn Technologies Inc. delivers proprietary vanadium flow batteries offering a variety of benefits over existing lithium and lead acid batteries
• The company’s growing intellectual property portfolio currently features four international PCT patents and five trademarks
• The total investment in the company’s technology has exceeded $2 million
• StorEn secured a $500,000 order to provide 30 kWh vanadium flow batteries to a renewable hydrogen plant at Queensland University of Technology in Australia
• The global battery energy storage market is forecast to reach $19.74 billion by 2027, recording a CAGR of 20.4% from 2020 to 2027
• StorEn is led by an executive team with decades of experience in the vanadium flow battery industry, including two previous startups exited to listed buyers
• The company is currently accepting investments through a Reg A+ offering on StartEngine Campaign, where it has raised more than $6.7 million from over 5,000 investors to date

StorEn Technologies delivers proprietary vanadium flow batteries aimed at revolutionizing the world of residential and industrial energy storage. With an expected life of 25 years and more than 15,000 cycles, the company’s batteries satisfy market demand for efficient, durable and cost-effective energy storage, enabling self-consumption of self-produced electricity and the transition toward a carbon-free economy. The company is currently accepting investments through a Reg A+ offering on StartEngine. For more information, view the company’s Offering Circular. To date, StorEn has raised more than $6.7 million from over 5,000 investors on the crowdfunding platform, along with venture capital from the ANYSEED Fund. StorEn’s growing intellectual property portfolio currently features four international PCT patents and five trademarks, securing its innovative IP in all major regions and countries in the world. A Disruptive Approach to Energy Storage StorEn’s patent-pending all-vanadium flow battery technology offers a variety of benefits over existing lithium and lead acid batteries, including:

• Eco-Friendly: StorEn vanadium flow batteries are 100% recyclable, featuring a 100% reusable electrolyte and low GHGs emissions
• Safe: The company’s batteries are both non-flammable and non-explosive
• Cost Effective: StorEn’s cost/kWh is comparable to that of lithium batteries, but its cost/cycle is up to four times lower than lithium batteries, thanks to the exceptional duration of over 25 years or 15,000 cycles
• Efficient: The company’s vanadium flow battery technology offers the highest power density thanks to MULTIGRIDS(TM), +35% in energy storage capacity with the same volume and +5% round-trip efficiency in harsh climate thanks to its proprietary THERMASTABLE(TM) geothermal design. StorEn’s solution is also virtually maintenance-free, leveraging its proprietary RESAFE(TM) and EQUILEVELS(TM) technologies.

StorEn batteries are modular and configurable in either 20kWh or 30kWh versions sharing the same Power Module, ensuring that customers only pay for the energy capacity they really need. The ability to connect additional modules allows for maximum flexibility. Traction in the Market To date, the total investment in the company’s technology has exceeded $2 million, and it is already putting these efforts to work. StorEn secured a $500,000 order in Australia to provide 30 kWh StorEn vanadium flow batteries to a renewable hydrogen plant at Queensland University of Technology (QUT), where researchers will develop safety standards for the future use of vanadium flow batteries. The first battery – the first of its kind in Australia – was installed in Brisbane in November 2020 at the National Battery Testing Centre (NBTC), a flagship project of the Future Battery Industries CRC. Additional units are being manufactured. StorEn has also entered into a supply chain deal with Multicom Resources, an Australian mining company which is the owner of two vanadium mines. Through this agreement, StorEn has secured the exclusive availability of vanadium for up to 20 years with either a price cap or at market price, whichever is lower. Capitalizing on the Australian government’s support to fulfil the country’s energy storage opportunity, Multicom’s subsidiary, Freedom Energy, has agreed to assemble StorEn batteries within Australia and distribute them widely across the wider Asia Pacific region. In addition to an initial pilot plant, Multicom has completed a concept design for a full-scale manufacturing facility for StorEn batteries. Market Opportunity The shift to renewable energy sources is on, with governments around the globe discussing and implementing initiatives to reduce dependence on fossil fuels. McKinsey & Company research suggests that, by 2035, more than 50% of global power generation will come from renewable sources. Spurred on by this transition, demand for reliable energy storage systems is expected to attain exponential growth in the coming years, positively influencing the energy storage industry landscape, according to Grand View Research. Data from Fortune Business Insights projects that the global battery energy storage market will reach $19.74 billion by 2027, recording a CAGR of 20.4% from 2020 to 2027. The research firm suggests that improving access to electricity across the globe will be a prominent trend shaping the growth trajectory of this market, which is particularly noteworthy for StorEn and its TITANstack™ grid-scale energy storage solution. Over a billion people still do not have access to electricity. The electrification of these unserved communities can become a reality with mini grids, using solar plus energy storage. StorEn’s vanadium flow batteries could be a key technology toward providing universal access to affordable, longer lasting and dependable energy. In support this critical mission, StorEn Technologies is a member of the Alliance for Rural Electrification and the Global Off-Grid Lighting Association. Management Team StorEn is led by an executive team with decades of experience in the vanadium flow battery industry. Founder Carlo Brovero has served as the company’s chief executive officer, treasurer and director since its inception in January 2017. From 2013 to 2019, Mr. Brovero served as a consultant for eCaral Ltd., a management consulting firm. From 2013 to 2015, he served as an advisory board member for Proxhima S.r.l., a vanadium flow battery company, which was sold to the Gala Group, a utility listed on the Milan Stock Exchange. From 2010 to 2016, Mr. Brovero served as International Sales and Marketing Director for iVis Technologies, the manufacturer of an excimer laser therapeutic and refractive platform for corneal surgery. He holds an MBA from Aston University in Birmingham, UK. Founder Angelo D’Anzi has served as StorEn’s chief technology officer and director since the company’s inception. He is primarily responsible for the technical development of StorEn’s products. Since May 2018, Mr. D’Anzi has also served as a director of Arco Fuel Cells S.r.l., where he is responsible for the company’s fuel cell technical development activities. Mr. D’Anzi co-founded vanadium flow battery company Proxhima in 2013. In 2000, he founded ROEN-EST, a fuel cell company that was eventually acquired by the Morphic Group, a cleantech holding company listed on the Stockholm Stock Exchange. Mr. D’Anzi holds 14 international patents and received the 2003 Sapio Award in the Energy and Transportation category. He holds an MBA from the LUISS Business School in Rome. Founder Gabriele Colombo has served as secretary of StorEn since its inception. Since 2012, he has also served in various roles ranging from regional manager to CEO with Leonardo Hispania S.A., a subsidiary of the Leonardo Group of Italy, an aerospace, defense and security conglomerate. Mr. Colombo co-founded vanadium flow battery company Proxhima in 2013. He holds an honors degree in computer engineering from the University of Pisa and a master’s degree in business leadership from the University of Genova. For more information, visit the company’s website at www.StorEn.tech. NOTE TO INVESTORS: The latest news and updates relating to StorEn Technologies are available in the company’s newsroom at https://ibn.fm/StorEn

• Bladder cancer is still the sixth most prevalent cancer in the U.S. in 2021
• The total number of new bladder cancer cases is expected to reach 83,730, with deaths totaling 17,200 this year
• Imagin Medical Inc. is hoping to offer a better standard of care for bladder cancer patients with its i/Blue Imaging System(TM) that improves visualization for resection, potentially lowering recurrence rates

According to American Cancer Society statistics, the number of cases of all types of cancer this year will total almost 1.9 million, with 608,570 deaths, or approximately 5,200 new cases and 1,670 deaths per day (https://ibn.fm/eDdCz). Of those numbers, bladder cancer remains the sixth most prevalent form of cancer in the United States, with an estimated 83,730 (4.4% of total) new cases and 17,200 (2.8% of total) estimated deaths in 2021 and a greater than 50% recurrence rate. The five-year relative survival rate (2010-2016) was reported at 77% – meaning that only 77% of diagnosed patients survived five years after diagnosis (https://ibn.fm/Y9NoK).

One company, Imagin Medical (CSE: IME) (OTCQB: IMEXF), is looking to disrupt the industry, changing how cystoscopies for bladder cancer are performed, with the goal of potentially lowering recurrence rates and ultimately helping improve patients’ lives and long-term outlook. The company’s i/Blue Imaging System(TM) is a breakthrough cancer visualization technology currently in the manufacturing stage with Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified contract manufacturer located in Maine. The project is on track for completion in 2022 (https://ibn.fm/q6YMg).

When patients present with symptoms that may be consistent with bladder cancer or other urinary-related conditions, the first step may be to perform a cystoscopy. The first symptom most commonly associated with bladder cancer is hematuria or blood in the urine. When coupled with other symptoms, doctors will perform further evaluations. These additional symptoms may include, but are not limited to:

• A need to urinate that is more frequent than usual
• Pain or burning during urination
• Feeling as if you need to urinate, or an increased urgency to urinate, even without a full bladder
• Having trouble urinating or a weak urine stream
• Needing to urinate many times during the night

For decades, cystoscopies have traditionally used white light illumination for visualization within the bladder. With this white light system, surgeons can visualize the bladder wall and detect and resect any protrusions or correct any inconsistencies, if necessary. However, flat tumors that do not protrude above the wall of the bladder cannot be visualized with white light alone, making it very difficult to perform a complete resection.

The introduction of blue light cystoscopies in 2010 has helped address this issue. Blue light cystoscopies use an FDA-approved contrast agent inserted into the bladder about an hour before the procedure. Once exposed to the blue light, the agent causes the cancerous cells to fluoresce, providing clear images of flat tumors and the margins. Blue light cystoscopy isn’t without its limitations – the current model on the market requires the surgeon or urologist to change views from white to blue light images to operate because the blue light image is not in real time and neither image provides proper orientation of the cancer within the bladder during resection. In addition, the cost of the current method is high and requires the purchase of proprietary, blue filtered cystoscopes that cannot be used for any other purpose.

Imagin Medical’s i/Blue Imaging System has the potential to revolutionize current cystoscopies by showing both white light and blue light images simultaneously side-by-side on the screen in real time, providing clear visualization of the fluoresced flat cancer cells and margins, in context within the bladder. This capability eliminates surgeons’ need to change between images and can potentially lead to lower recurrence rates and help assure a better standard of care and future for bladder cancer patients. In addition, the i/Blue System will come at an overall lower system cost and, because it will adapt to most endoscopes on the market, will allow hospitals and doctor’s offices to make use of scopes they already own, adding to the savings.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF